Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONgenital Cytomegalovirus: Efficacy of antiviral treatment in a non-Randomized Trial with historical control group
2013-003068-30Phase 3Completed
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of valganciclovir in congenital cytomegalovirus infection (cCMV) and sensorineural hearing loss (SNHL) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Status of sensorineural hearing loss at 18–22 months. Started Sep 2013; status: completed.
02
Drugs
valganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on 2013-003068-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003068-30.